GlassScriptPhysician profile
Jeffrey J Kropp
NPI 1902083538
$3,724.09
in general payments reported to CMS, 2019-2025
30 companies · $604 in 2025
The $604 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $259 · 2021: $202 · 2022: $402 · 2023: $828 · 2024: $660 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,053 · Education: $39.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,052.82 |
| Education | $39.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $880.06 | 2019-2025 | Veltassa |
| Amgen INC. | $585.36 | 2019-2025 | Tavneos, Aranesp, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $397.58 | 2019-2025 | Farxiga, Lokelma, Evusheld |
| Otsuka America Pharmaceutical, INC. | $352.60 | 2019-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $191.57 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $161.38 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $111.96 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $108.28 | 2019-2023 | Auryxia |
| Horizon Therapeutics Plc | $104.15 | 2019-2023 | Krystexxa |
| Nxstage Medical, INC. | $72.57 | 2024-2025 | Liberty Select Cycler, Nxstage System One |
| Pfizer INC. | $62.72 | 2019 | |
| Fresenius USA Marketing, INC. | $62.58 | 2019-2024 | Velphoro |
| Ardelyx, INC. | $59.42 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $58.59 | 2023-2024 | Jardiance |
| Travere Therapeutics, INC. | $58.33 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $54.10 | 2023 | Jesduvroq, Benlysta |
| Alexion Pharmaceuticals, INC. | $49.86 | 2019-2024 | Ultomiris |
| Opko Pharmaceuticals, LLC | $46.74 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $46.63 | 2025 | |
| Mallinckrodt Enterprises LLC | $45.06 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.56 | 2022-2023 | Gattex |
| Daiichi Sankyo INC. | $36.52 | 2019 | |
| Renalytix Ai, INC. | $24.96 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Arbor Pharmaceuticals, INC. | $24.04 | 2020 | |
| Lundbeck LLC | $21.42 | 2019 | |
| Apellis Pharmaceuticals, INC. | $17.01 | 2025 | |
| Veloxis Pharmaceuticals, INC. | $16.09 | 2024 | Envarsus |
| Alnylam Pharmaceuticals INC. | $15.63 | 2019 | |
| Cormedix INC. | $14.32 | 2024 | Defencath |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Kropp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.